Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript
Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.
How this was made

The 30-second read
Why it matters
Earnings beat expectations with strong sales and cash, likely supporting share price appreciation.
Market read
First disclosure of quarterly financials provides fresh data for traders.
What to watch
Potential regulatory or manufacturing bottlenecks for CAR‑T scale‑up.
Background
Legend Biotech presented Q3 2026 results, focusing on CARVYKTI performance and pipeline updates.
Ticker impact
Q3 2026 earnings call disclosed CARVYKTI net trade sales of $710M (+36% YoY) and $853M cash balance.
likely upward pressure as market prices in robust revenue growth
First report of quarterly sales and cash figures, material for valuation.
Market effects
Boosts outlook for cell‑therapy and biotech sector.
Positive for US biotech equities.
Highlights growth in CAR‑T therapies worldwide.
Counterpoint
High valuation multiples may limit upside despite sales growth.
Key entities
- CompanyLegend Biotech
US‑listed biotech developing CAR‑T therapies.


